Adolf-Butenandt Institute, Department of Biochemistry Laboratory for Alzheimer's and Parkinson's Disease Research Ludwig-Maximilians University Munich, Germany chaass@pbm.med.uni-muenchen.de
Clinical trials of a vaccine against Alzheimer disease came to an abrupt halt this year when several patients developed inflammation in the brain. Now, the first data from the trial and a mouse study brighten the outlook for this spectacular and simple treatment approach (pages 1263−1269 and 1270−1275).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
peptide target amyloid-
